Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-924 in Advanced KRAS-Mutant Solid Tumors
NCT07629960Phase 2Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Jun 2026
- Primary completion
- Sep 2029
- Countries
- 2
01
Overview
A Phase 2 trial of BLU-924 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Blueprint Medicines. Started Jun 2026; status: recruiting.
02
Drugs
BLU-924
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07629960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629960.